A 25-gene classifier predicts overall survival in resectable pancreatic cancer by BIRNBAUM, David et al.
HAL Id: hal-01787872
https://hal.archives-ouvertes.fr/hal-01787872
Submitted on 7 May 2018
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
A 25-gene classifier predicts overall survival in resectable
pancreatic cancer
David Birnbaum, Pascal Finetti, Alexia Lopresti, Marine Gilabert, Flora
Poizat, Jean-Luc Raoul, Jean-Robert Delpero, Vincent Moutardier, Daniel
Birnbaum, Emilie Mamessier, et al.
To cite this version:
David Birnbaum, Pascal Finetti, Alexia Lopresti, Marine Gilabert, Flora Poizat, et al.. A 25-gene
classifier predicts overall survival in resectable pancreatic cancer. BMC Medicine, BioMed Central,
2017, 15 (1), ￿10.1186/s12916-017-0936-z￿. ￿hal-01787872￿
RESEARCH ARTICLE Open Access
A 25-gene classifier predicts overall survival
in resectable pancreatic cancer
David J. Birnbaum1,2,3, Pascal Finetti1, Alexia Lopresti1, Marine Gilabert4, Flora Poizat5, Jean-Luc Raoul4,
Jean-Robert Delpero3,6, Vincent Moutardier2,3, Daniel Birnbaum1, Emilie Mamessier1† and François Bertucci1,3,4,7*†
Abstract
Background: Pancreatic carcinoma is one of the most lethal human cancers. In patients with resectable tumors,
surgery followed by adjuvant chemotherapy is the only curative treatment. However, the 5-year survival is 20%.
Because of a strong metastatic propensity, neoadjuvant chemotherapy is being tested in randomized clinical trials.
In this context, improving the selection of patients for immediate surgery or neoadjuvant chemotherapy is crucial,
and high-throughput molecular analyses may help; the present study aims to address this.
Methods: Clinicopathological and gene expression data of 695 pancreatic carcinoma samples were collected from
nine datasets and supervised analysis was applied to search for a gene expression signature predictive for overall
survival (OS) in the 601 informative operated patients. The signature was identified in a learning set of patients and
tested for its robustness in a large independent validation set.
Results: Supervised analysis identified 1400 genes differentially expressed between two selected patient groups in
the learning set, namely 17 long-term survivors (LTS; ≥ 36 months after surgery) and 22 short-term survivors (STS;
dead of disease between 2 and 6 months after surgery). From these, a 25-gene prognostic classifier was developed,
which identified two classes (“STS-like” and “LTS-like”) in the independent validation set (n = 562), with a 25%
(95% CI 18–33) and 48% (95% CI 42–54) 2-year OS (P = 4.33 × 10–9), respectively. Importantly, the prognostic value
of this classifier was independent from both clinicopathological prognostic features and molecular subtypes in
multivariate analysis, and existed in each of the nine datasets separately. The generation of 100,000 random gene
signatures by a resampling scheme showed the non-random nature of our prognostic classifier.
Conclusion: This study, the largest prognostic study of gene expression profiles in pancreatic carcinoma, reports a
25-gene signature associated with post-operative OS independently of classical factors and molecular subtypes. This
classifier may help select patients with resectable disease for either immediate surgery (the LTS-like class) or
neoadjuvant chemotherapy (the STS-like class). Its assessment in the current prospective trials of adjuvant and
neoadjuvant chemotherapy trials is warranted, as well as the functional analysis of the classifier genes, which may
provide new therapeutic targets.
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Background
With a mortality rate close to the incidence rate
(331,000 deaths worldwide for 338,000 new cases in
2012 [1]), pancreatic carcinoma is one of the most lethal
human cancers. Advances in systemic chemotherapy and
radiotherapy provided limited improvement in survival,
and the 5-year overall survival (OS) remains close to 5%.
Only 50% of newly diagnosed patients have a non-
metastatic disease with either a resectable or borderline
resectable tumor (20%) or an unresectable locally-
advanced tumor (30%) [2]. In patients with a resectable
tumor, complete surgical removal followed by adjuvant
chemotherapy is the only curative treatment. However,
most of the patients display distant relapse; the median
OS remains 23 months on average, and the 5-year
survival is 20%. The mortality of surgery has decreased
during the last 30 years, but its morbidity remains at
approximately 50% [3].
The high rates of patients with stage IV and experien-
cing distant relapses after surgery in non-metastatic
stages along with preclinical data suggest that metastatic
spread may precede local tumor formation [4]. This has
led to the emerging consensus that pancreatic cancer is
a systemic disease already at diagnosis. More effective
systemic therapies should confer an increased likelihood
of cure after resection. Neoadjuvant chemotherapy,
standardly used for borderline resectable and unresect-
able locally advanced diseases [2], is being tested in
resectable tumors with several objectives [5], including
early treatment of occult micrometastases, avoidance of
unnecessary and morbid resection for rapidly metasta-
sizing tumors, improvement of the likelihood of margin-
negative resection, and better chemotherapy delivery than
in adjuvant settings when surgical complications may delay
or worsen chemotherapy tolerability. Other advantages
include the ability to assess tumor response and to search
for biological predictors for pathological response, which is
associated with survival [6, 7]. Neoadjuvant chemotherapy
provided interesting results in resectable pancreatic cancer
in a few institutional prospective phase II studies [8–10],
and randomized phase II/III studies are ongoing [2]. How-
ever, this approach faces potential hurdles such as a
possible missed opportunity for curative surgery and the
absence of surgical staging. In this context, improving our
ability to select patients for either immediate surgery or
neoadjuvant chemotherapy is crucial, and represents an
area of high need and intense research [2].
The current prognostic factors are clinicopathological,
notably based on the American Joint Committee on
Cancer (AJCC) tumor, node and metastasis staging, and
the criteria used for immediate surgery are technical
(mainly based on the vascular involvement assessment),
clinical (e.g., based on performance status), and biological
(e.g., based on CA19-9 value). However, the criteria’s
ability to consistently predict a patient’s outcome is lim-
ited, with substantial heterogeneity within the so-defined
prognostic classes [11]. Actually, no prognostic or predict-
ive biomarker has yet been established for pancreatic
cancer. High-throughput molecular analyses revealed the
extensive heterogeneity of cancers, and notably pancreatic
cancer. Key molecular alterations have been identified,
such as KRAS, TP53, SMAD4, CDKN2A, and ARID1A
mutations and GATA6 amplification [12, 13], but they re-
main without clinical application to date. Several studies
of gene expression profiling have also been reported [14],
mainly focused on the comparison of cancer versus nor-
mal pancreatic tissues. A few prognostic gene expression
signatures have been developed [15–24], in general from
small sample series and without validation in independent
sets, or with validation in limited tumor sets. Biologic-
ally relevant molecular subtypes have been identified
[16, 25, 26], and associated with OS [27]. However,
identifying molecular predictors to aid in patient care
remains necessary.
Here, we collected data of 695 pancreatic carcinoma
samples from gene expression datasets, and searched for a
gene expression signature predictive for post-operative OS.
Methods
Gene expression datasets
We retrospectively collected clinicopathological and gene ex-
pression data of clinical pancreatic carcinoma samples from
nine publicly available datasets [15, 16, 20, 21, 23, 25, 28–30]
from the National Center for Biotechnology Informa-
tion/Genbank Gene Expression Omnibus, ArrayEx-
press, European Genome-phenome Archive, and The
Cancer Genome Atlas (TCGA) databases (Additional
file 1: Table S1). Samples had been profiled using
whole-genome DNA microarrays (Affymetrix or Agilent)
and RNA-Seq (Illumina). The complete dataset contained
695 samples, including 601 operated primary cancer
samples with available survival data. The study was
approved by our institutional board.
Gene expression data analysis
Data analysis required pre-analytic processing. First, we
normalized each DNA microarray-based dataset separ-
ately, by using quantile normalization for the available
processed Agilent data, and Robust Multichip Average
[31] with the non-parametric quantile algorithm for the
raw Affymetrix data. Normalization was performed in R
using Bioconductor and associated packages. Then, we
mapped hybridization probes across the different techno-
logical platforms. We used SOURCE [32] and NCBI
EntrezGene [33] to retrieve and update the Agilent anno-
tations, and NetAffx Annotation files [34] for the Affyme-
trix annotations. The probes were then mapped according
to their EntrezGeneID. When multiple probes represented
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the same GeneID, we retained the one with the highest
variance in a particular dataset. For the TCGA, Bailey’s
and Kirby’s data, we used the available normalized
RNA-Seq data that we log2-transformed.
We defined the molecular subtypes of all pancreatic
cancer samples in each dataset separately as defined in the
original publications, i.e., the three Collisson’s subtypes
[16] were classical, quasi-mesenchymal, and exocrine-like,
the two Moffitt’s epithelial subtypes [26] were basal-like
and classical, and the four Bailey’s subtypes [25] were
squamous, pancreatic progenitor, immunogenic, and
aberrantly differentiated endocrine exocrine (ADEX). To
identify a prognostic expression signature, we applied a
supervised analysis using learning and validation sets. The
learning set was a subset (n = 39) of the Bailey’s and
TCGA RNA-Seq datasets that included samples from pa-
tients with survival of at least 36 months after surgery
(long-term survivors (LTS); n = 17) and from patients dead
of disease between 2 and 6 months after surgery (short-
term survivors (STS); n = 22). The 562 other samples with
available survival data from the other datasets were gath-
ered and used as an independent validation set. Samples
of the learning set were pooled before supervised analysis
by using COMBAT (empirical Bayes), included in the
inSilicoMerging R/Bioconductor package, as a batch
effects removal method. The final merged set included
15,291 genes in log2-transformed data. The accuracy of
normalization was controlled by principal component
analysis (Additional file 2: Figure S1). The supervised
analysis compared the expression profiles of 15,291 genes
between the 22 STS samples and the 17 LTS samples
using a moderated t-test with empirical Bayes statistic
included in the Limma R packages. False discovery rate
was applied to correct for the multiple testing hypothesis
and significant genes were defined by the following
thresholds: P < 5%, false discovery rate < 25%, and fold
change superior to |2x|. Ontology analysis of the resulting
1400-gene list was based on the gene ontology (GO)
biological processes of the Database for Annotation,
Visualization and Integrated Discovery (DAVID) [35]. We
then developed a prognostic classifier while minimizing
the number of retained genes. Starting from the resulting
1400-gene list, we used logistic regression analysis with
Least Absolute Shrinkage and Selection Operator [36]
(LASSO), which is a selection method that handles high-
dimensional regression variables with no prior feature se-
lection step by shrinking all regression coefficients toward
zero, and thus forcing many regression variables to be
exactly zero. The penalty regularization parameter λ was
chosen via the cross-validation routine cv.glmnet before
running the main algorithm implemented in the R pack-
age glmnet version 1.9-8, with an n-fold equal to 10. The λ
value was finalized by using the lambda.min, which is the
value of lambda giving minimum mean cross-validated
error (lambda.min was 0.0153). The resulting classifier
allowed the definition of two classes of samples, namely
the predicted STS-like class and the predicted LTS-like
class. Its robustness was assessed in the independent
validation set (n = 562) by classifying each sample in each
dataset separately as STS-like or LTS-like. Since a few
studies have indicated that many gene signatures were
random noise signatures [37, 38], we evaluated whether
our prognostic 25-gene signature was not inferior to ran-
dom signatures. A resampling scheme was used to gener-
ate 100,000 random 25-gene signatures within the 1400
genes differentially expressed identified by supervised ana-
lysis in the learning set. Each random signature was then
applied to the validation set to determine its significance
level in prognostic terms for OS. We then measured the
proportion of random signatures with a P value inferior to
the P value from our 25-gene signature.
Statistical analysis
Associations between tumor groups and clinicopatholog-
ical features were analyzed using the t-test or the Fisher’s
exact test when appropriate. Overall survival (OS) was
calculated from the date of diagnosis to the date of death
from pancreatic cancer. Follow-up was measured from
the date of diagnosis to the date of last news for living
patients. Survivals were calculated using the Kaplan–
Meier method and were compared with the log-rank
test. Uni- and multivariate survival analyses were
performed using Cox regression analysis (Wald test).
Variables tested in univariate analyses included patient
age at time of diagnosis (>60 vs. ≤ 60 years), sex (male vs.
female), AJCC clinical stage (2, 3, and 4 vs. 1), pathological
features including pathological type (others vs. ductal),
tumor size (pT2, T3, and pT4 vs. T1), lymph node status
(positive vs. negative), grade (2, 3, and 4 vs. 1), our 25-gene
classification (STS-like vs. LTS-like), and the different mo-
lecular subtype classifications. Variables with a P value
lower than 0.05 were tested in multivariate analysis. All
statistical tests were two-sided at the 5% level of signifi-
cance. Statistical analysis was performed using the survival
package (version 2.30) in the R software (version 2.15.2)
[39]. We followed the reporting REcommendations for
tumor MARKer prognostic studies (REMARK criteria)
[40]. A Sweave report describing the analysis of gene
expression data and the associated statistical analysis is
available as Additional file 3 (Supplementary Text).
Results
Patient population
We collected nine retrospective/prospective public
whole-genome mRNA expression datasets of 695
pancreatic samples, and focused our analysis on the 601
cancer samples from patients operated from the outset
and with available survival. As shown in Table 1, the
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majority of patients were aged 60 years or older, and 54%
were male. Most cases (96%) were AJCC stage 1 or 2,
ductal type (98%), and grade 2 (55%). All but one case had
been treated by front-line surgery, and the majority of
tumors were pT2 (16%) or pT3 (77%), and pN-positive
(69%). All Bailey’s, Moffitt’s, and Collison’s molecular sub-
types were represented. A total of 354 patients died. The
median OS was 20 months (range, 1–156), and the 2-year
OS was 40% (95% CI 36–45).
Identification of a prognostic expression signature
We searched for a gene signature associated with OS.
Supervised analysis was performed in a learning set of
39 samples selected to represent the two opposite
groups of patients, including 17 LTS and 22 STS.
Analysis identified 1400 genes differentially expressed
between the two groups (Additional file 4: Table S2). All
associated GO biological processes are shown in
Additional file 5: Table S3, and the top 40 processes
are shown in Table 2. The robustness of those genes
was tested by testing their ability to classify the LTS and
STS samples from the other independent datasets. Out of
the 67 samples classified, 49 (76%) were accurately classi-
fied, suggesting strong robustness (P = 7.68 × 10–5, Fisher’s
exact test).
To render this signature more easily applicable in
clinics, we built a multigene classifier from the 1400-
gene list. Logistic regression analysis retained 25 genes
(Table 3), including 12 and 13 genes respectively upregu-
lated and downregulated in the STS samples. As
expected, the classifier based on these 25 genes sorted
with 100% accuracy those 39 patients into two classes,
with STS-like including all STS patients and LTS-like
including all LTS patients.
We assessed the gene overlap between our 25-gene
signature and the three molecular subtype classifiers
[16, 25, 26] and five other signatures recently pub-
lished that displayed robust and independent prognos-
tic value [15, 17, 20, 22, 30]. As shown in Additional
file 6: Figure S2, there was no overlap with the five
signatures, and the overlap with the molecular subtype
classifiers was very low (0 gene with Collisson, 1 with
Moffitt stroma, 2 with Moffitt tumor, and 3 with Bailey).
Validation of the 25-gene classifier and clinicopathological
associations
We tested the 25-gene prognostic classifier in the inde-
pendent validation set of 562 patients whose clinicopatho-
logical characteristics were close to those of the learning
set (Additional file 7: Table S4) and with a 2-year OS of
39% (95% CI 35–44; Fig. 1a). The classifier sorted the 562
patients into two classes, STS-like (n = 216; 38%) and
LTS-like (n = 346; 62%), with a 2-year OS of 25%
(95% CI 18–33) and 48% (95% CI 42–54), respectively
Table 1 Patient and tumor clinicopathological characteristics of
601 samples
Characteristics All (n = 601)
Age at diagnosis, years
≤ 60 118 (32%)
> 60 246 (68%)
Sex
Female 170 (46%)
Male 197 (54%)
AJCC Stage
1 62 (12%)
2 431 (84%)
3 10 (2%)
4 12 (2%)
Pathological type
Ductal 537 (98%)
Othera 11 (2%)
Pathological grade
1 33 (12%)
2 154 (55%)
3 91 (32%)
4 2 (1%)
Pathological tumor size (pT)
pT1 18 (5%)
pT2 62 (16%)
pT3 302 (77%)
pT4 11 (3%)
Pathological lymph node status (pN)
Negative 141 (31%)
Positive 310 (69%)
Collisson subtypes
Classical 234 (39%)
Exocrine-like 211 (35%)
Quasi-mesenchymal 156 (26%)
Moffitt subtypes, ‘type’
Basal-like 232 (39%)
Classical 369 (61%)
Bailey subtypes
ADEX 140 (23%)
Immunogenic 104 (17%)
Pancreatic progenitor 142 (24%)
Squamous 215 (36%)
Deceased 354 (59%)
2-year OS (95% CI) 40% (36–45)
Median OS, months (range) 20 (1–156.4)
aOther: 8 neuroendocrine tumors, 2 acinar cell carcinomas, 1 intraductal
tubulopapillary neoplasm
ADEX aberrantly differentiated endocrine exocrine, AJCC American Joint
Committee on Cancer, CI confidence interval, OS overall survival
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(P = 4.33 × 10–9, log-rank test; Fig. 1b), thus confirm-
ing its prognostic value. The respective median OS were
15 months (range, 1–104) and 23 months (range, 1–156).
Interestingly, in each of the nine datasets separately, the 2-
year OS was shorter in the STS-like class than in the LTS-
like class, and the difference was or tended to be significant
Table 2 Top 40 gene ontology (GO) biological processes associated with the 1400 genes differentially expressed between the
short-term survivor (STS) and long-term survivor (LTS) samples of the learning set
GO:BP TermsID GO:BP Terms N P value Status STS vs. LTS
GO:0030198 Extracellular matrix organization 70 9.15 × 10–26 Up
GO:0007155 Cell adhesion 75 2.46 × 10–22 Up
GO:0022617 Extracellular matrix disassembly 35 2.70 × 10–18 Up
GO:0008544 Epidermis development 25 1.04 × 10–17 Up
GO:0030574 Collagen catabolic process 26 2.78 × 10–17 Up
GO:0006955 Immune response 50 1.44 × 10–16 Up
GO:0006954 Inflammatory response 52 2.34 × 10–16 Up
GO:0030199 Collagen fibril organization 19 6.76 × 10–16 Up
GO:0018149 Peptide cross-linking 10 1.23 × 10–10 Up
GO:0006935 Chemotaxis 22 2.34 × 10–10 Up
GO:0010951 Negative regulation of endopeptidase activity 23 6.65 × 10–10 Up
GO:0030216 Keratinocyte differentiation 14 3.24 × 10–9 Up
GO:0010466 Negative regulation of peptidase activity 8 1.47 × 10–8 Up
GO:0001501 Skeletal system development 22 2.51 × 10–8 Up
GO:0007160 Cell-matrix adhesion 19 1.30 × 10–7 Up
GO:0000278 Mitotic cell cycle 50 1.71 × 10–7 Up
GO:0008283 Cell proliferation 42 1.86 × 10–7 Up
GO:0031124 Mrna 3-end processing 600 2.19 × 10–7 Up
GO:0008284 Positive regulation of cell proliferation 45 3.26 × 10–7 Up
GO:0001525 Angiogenesis 32 3.31 × 10–7 Up
GO:0019228 Neuronal action potential 6 1.26 × 10–6 Down
GO:0007409 Axonogenesis 12 1.13 × 10–6 Down
GO:0007628 Adult walking behavior 7 1.09 × 10–6 Down
GO:0007212 Dopamine receptor signaling pathway 5 7.83 × 10–7 Down
GO:0006906 Vesicle fusion 10 4.63 × 10–7 Down
GO:0030073 Insulin secretion 9 5.27 × 10–8 Down
GO:0007274 Neuromuscular synaptic transmission 6 5.20 × 10–8 Down
GO:0007399 Nervous system development 27 1.44 × 10–8 Down
GO:0014047 Glutamate secretion 9 5.89 × 10–9 Down
GO:0007626 Locomotory behavior 15 4.46 × 10–9 Down
GO:0086010 Membrane depolarization during action potential 8 1.71 × 10–9 Down
GO:0031018 Endocrine pancreas development 12 1.16 × 10–9 Down
GO:0017158 Regulation of calcium ion-dependent exocytosis 10 9.94 × 10–10 Down
GO:0006112 Energy reserve metabolic process 20 4.05 × 10–11 Down
GO:0017157 Regulation of exocytosis 13 1.60 × 10–11 Down
GO:0006813 Potassium ion transport 15 3.94 × 10–12 Down
GO:0071805 Potassium ion transmembrane transport 17 1.97 × 10–13 Down
GO:0016079 Synaptic vesicle exocytosis 17 4.00 × 10–15 Down
GO:0007269 Neurotransmitter secretion 19 7.04 × 10–16 Down
GO:0007268 Synaptic transmission 66 2.33 × 10–37 Down
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(Additional file 8: Figure S3). To assess the likelihood of
our 25-gene signature as a non-random signature, we gen-
erated by a resampling scheme 100,000 random gene sig-
natures from the list of 1400 genes differentially expressed
and tested their prognostic value in the validation set.
None of the random signatures was more significant than
the data-derived 25-gene signature, suggesting that the
latter represented an optimal prognostic combination.
We searched for associations between the 25-gene
signature-based classification and the clinicopathological
Table 3 List of 25 genes included in our prognostic classifier
Symbol Description Cytoband Expression status
GPR87 G protein-coupled receptor 87 3q24 Up STS vs. LTS
KRT13 keratin 13, type I 17q21.2 Up STS vs. LTS
RAC2 ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2) 22q13.1 Up STS vs. LTS
C16orf74 chromosome 16 open reading frame 74 16q24.1 Up STS vs. LTS
NAMPT nicotinamide phosphoribosyltransferase 7q22.3 Up STS vs. LTS
DHRS9 dehydrogenase/reductase (SDR family) member 9 2q31.1 Up STS vs. LTS
HIST2H2BF histone cluster 2, H2bf 1q21.2 Up STS vs. LTS
TREM2 triggering receptor expressed on myeloid cells 2 6p21.1 Up STS vs. LTS
ZDHHC20 zinc finger, DHHC-type containing 20 13q12.11 Up STS vs. LTS
CD180 CD180 molecule 5q12 Up STS vs. LTS
ADGRG6 adhesion G protein-coupled receptor G6 6q24.1 Up STS vs. LTS
APBB1IP amyloid beta (A4) precursor protein-binding, family B, member 1 interacting protein 10p12.1 Up STS vs. LTS
EGR3 early growth response 3 8p23-p21 Down STS vs. LTS
MACROD2 MACRO domain containing 2 20p12.1 Down STS vs. LTS
EPHA7 EPH receptor A7 6q16.1 Down STS vs. LTS
RASGEF1A RasGEF domain family, member 1A 10q11.21 Down STS vs. LTS
SYNM synemin, intermediate filament protein 15q26.3 Down STS vs. LTS
S100A1 S100 calcium binding protein A1 1q21 Down STS vs. LTS
WNK2 WNK lysine deficient protein kinase 2 9q22.3 Down STS vs. LTS
RAMP2 receptor (G protein-coupled) activity modifying protein 2 17q12-q21.1 Down STS vs. LTS
SOCS2 suppressor of cytokine signaling 2 12q Down STS vs. LTS
COL28A1 collagen, type XXVIII, alpha 1 7p21.3 Down STS vs. LTS
B4GALT6 UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 6 18q11 Down STS vs. LTS
PLCB4 phospholipase C, beta 4 20p12 Down STS vs. LTS
MTURN maturin, neural progenitor differentiation regulator homolog (Xenopus) 7p14.3 Down STS vs. LTS
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Fig. 1 Overall survival (OS) in the validation set according to our prognostic 25-gene classifier. Kaplan–Meier OS curves in all patients (a) and in
all patients according to our prognostic classifier (STS-like and LTS-like classes) (b). The P values of the log-rank test are indicated
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variables of samples. As shown in Table 4, no association
was found with patient age and sex, AJCC stage, patho-
logical type, tumor size, and lymph node status. By con-
trast, there were more grade 3 tumors (P = 1.50 × 10–3) in
the STS-like class, and more aggressive molecular sub-
types (Baileys’ squamous, Collison’ quasi-mesenchymal,
and Moffitt’s basal-like; P < 0.05).
Uni- and multivariate prognostic analyses
We compared the prognostic value of our 25-gene clas-
sifier with that of other clinicopathological variables in
the validation set. In univariate analysis (Table 5), three
variables were associated with OS (Wald test), namely
the AJCC clinical stage (P = 4.71 × 10–3), the patho-
logical pN status (P = 1.24 × 10–4), and our 25-gene
classifier (P = 7.47 × 10–9). The hazard ratio (HR) for
death was 1.93 (95% CI 1.55–2.42) in the STS-like vs.
LTS-like classes. In multivariate analysis, only our classi-
fier (P = 6.33 × 10–7) and the pN status (P = 2.95 × 10–2)
remained significant, suggesting an independent prognos-
tic value. The stratification of patients according to both
the classifier and the AJCC stage identified classes with
different 2-year OS (Additional file 9: Figure S4). For
example, in patients with stage 1 tumor, the 2-year OS
was 42% in the STS-like class (42%) and 73% in the
LTS-like class (P = 6.74 × 10–3, log-rank test). Stage 2
patients were similarly subdivided into STS- and LTS-
like with a 21% and 46% 2-year OS (P = 4.37 × 10–7,
log-rank test), respectively.
Given the association between the molecular subtypes
and the 25-gene classifier, we compared their respective
prognostic performance. In univariate analysis, the three
molecular subtype classifiers confirmed their prognostic
value in this large sample set (Additional file 10: Figure S5).
However, in multivariate analysis including the four multi-
gene classifiers, only our 25-gene classifier remained signifi-
cant (P = 6.33 × 10–6, Wald test, Table 5) with a HR of 1.77
(95% CI 1.38–2.26). As shown in Fig. 2, it affected the
clinical outcome of all molecular subtypes of all three
classifications, except the Bailey’s progenitor subtype.
Discussion
Pancreatic carcinoma is a heterogeneous disease with
high metastatic propensity and poor prognosis. In pa-
tients with resectable disease, the development of effect-
ive systemic therapies is crucial. During the last decades,
several retrospective studies [41] and a few prospective
phase II studies [8–10] have suggested the potential
benefit of neoadjuvant chemotherapy, and large random-
ized phase II/III trials are ongoing. In this context, a
major challenge is to improve the imperfect current
prognostic factors to aid in therapeutic decision-making,
notably regarding the decision for immediate surgery
followed by chemotherapy or neoadjuvant chemotherapy
followed by surgery. Here, we have analyzed whole-
genome expression profiles of 601 pancreatic carcinoma
samples from operated patients, and identified a robust
25-gene classifier associated with post-operative OS
independently of classical prognostic factors and mo-
lecular subtypes. To our knowledge, this study is by far
the largest prognostic study of gene expression profiles
in pancreatic carcinoma.
Gene expression profiling remains today the most
promising and successful high-throughput molecular ap-
proach to identify new prognostic tools in early-stage
cancers. Multigene signatures are already marketed, such
as Oncotype™ in breast cancer or Coloprint™ in colon
cancer, yet no similar signature is available in pancreatic
carcinoma. The paucity of tumor specimens available for
analysis explains the relatively small number of samples
profiled in previous prognostic studies, with 102 samples
in the largest one [20] to use supervised analysis, and
328 in the Australian ICGC study [25], which identified
prognostic molecular subtypes by unsupervised analysis.
We overcame the problem by pooling nine public
datasets, representing a total of 601 operated primary
cancers with available follow-up, and allowing the use of
a learning set and a validation set in the supervised ana-
lysis. Our series displayed classical clinicopathological
characteristics and poor prognosis with a 40% 2-year
OS. The learning set, which included only 39 samples,
was remarkably small compared with the validation set;
this might have reduced our ability to capture the best
genes for the classifier. However, it was carefully
designed to contain two groups with distinct aggressive-
ness, namely a LTS group after surgery and a STS group,
and to contain samples profiled using the same technol-
ogy (RNA-Seq). Such design likely explains the large
number of genes (1400) differentially expressed between
the two patient groups despite the correction for the
multiple testing hypothesis, and the robustness of our
final signature in the validation set. A similar design had
been used previously [20] by comparing primary tumors
from metastatic versus non-metastatic patients. The size
of our series allowed testing of the classifier in a large
independent validation set of 562 samples with multi-
variate analysis and increased statistical power. For com-
parison, the other prognostic expression signatures
published to date in pancreatic cancer [15–24] were de-
fined in learning sets including 6–70 clinical samples,
then tested in validation sets including 67–246 samples,
with inconstant multivariate analysis.
We first identified 1400 genes differentially expressed
between the STS and LTS samples. From this gene list, a
25-gene classifier was developed, identifying two classes,
namely STS-like and LTS-like. The prognostic value was
verified in the independent validation set, in which the
two classes, STS-like (38% of samples) and LTS-like
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Table 4 Associations of our prognostic classification with clinicopathological features (validation set)
Characteristics n LTS-like (n = 346) STS-like (n = 216) P value
Age at diagnosis 0.219
≤ 60 108 64 (31%) 44 (38%)
> 60 217 145 (69%) 72 (62%)
Sex 0.419
Female 157 105 (50%) 52 (44%)
Male 171 106 (50%) 65 (56%)
AJCC stage 0.759
1 54 35 (12%) 19 (11%)
2 403 255 (84%) 148 (85%)
3 10 5 (2%) 5 (3%)
4 11 8 (3%) 3 (2%)
Pathological type 0.087
Ductal 504 308 (98%) 196 (100%)
Other 6 6 (2%) 0 (0%)
Pathological grade 1.50 × 10–3*
1 27 24 (16%) 3 (3%)
2 138 90 (59%) 48 (54%)
3 75 38 (25%) 37 (42%)
4 2 1 (1%) 1 (1%)
Pathological tumor size (pT) 0.879
pT1 15 9 (4%) 6 (5%)
pT2 57 36 (16%) 21 (16%)
pT3 281 181 (78%) 100 (76%)
pT4 11 6 (3%) 5 (4%)
Pathological lymph node status (pN) 0.824
Negative 123 79 (30%) 44 (29%)
Positive 291 183 (70%) 108 (71%)
Collisson subtypes 1.00 × 10–6*
Classical 223 130 (38%) 93 (43%)
Exocrine-like 194 147 (42%) 47 (22%)
Quasi-mesenchymal 145 69 (20%) 76 (35%)
Moffitt subtypes, ‘type’ 7.80 × 10–15*
Basal-like 214 88 (25%) 126 (58%)
Classical 348 258 (75%) 90 (42%)
Bailey subtypes 1.00 × 10–6*
ADEX 128 114 (33%) 14 (6%)
Immunogenic 101 69 (20%) 32 (15%)
Pancreatic progenitor 133 90 (26%) 43 (20%)
Squamous 200 73 (21%) 127 (59%)
2-year OS (95% CI) 562 48% (42–54) 25% (0.18–0.33) 4.33 × 10–9*
Median OS, months (range) 562 22.8 (1–156.4) 15.0 (1–103.92)
ADEX aberrantly differentiated endocrine exocrine, CI confidence interval, LTS long-term survivors, STS short-term survivors, OS overall survival
*Statistically significant
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(62%), showed a different 2-year OS (25% in the STS-
like and 48% in the LTS-like). Interestingly, and by con-
trast to the other published studies in the field, this
prognostic value existed in each of the nine datasets
considered separately. As expected, the other variables
significant in univariate analysis included the AJCC stage
and the pathological lymph node status. The patho-
logical type (other vs. ductal) was not significant (HR
0.36 with P = 0.151) because of the small percentage
(1%) of “other” types. Interestingly, all six “other” type
samples were classified in the LTS-like class, in agree-
ment with the better prognosis of neuroendocrine tu-
mors. Importantly, the OS analysis was not modified
when limited to the 504 ductal samples with a 27% 2-
year OS in the STS-like and 48% in the LTS-like. Our
25-gene classifier displayed an independent prognostic
value. Interestingly, it outperformed the molecular sub-
types in multivariate analysis and identified patients with
shorter and longer survival in all subtypes but one,
highlighting substantial heterogeneity in each of them.
None of the 100,000 25-gene signatures randomly gener-
ated by a resampling scheme was more significant than
the data-derived 25-gene signature, suggesting that this
latter represented a non-random optimal prognostic
combination.
Ontology analysis of the 25 genes revealed interesting
pathways, such as pathways related to the metastatic
process (extracellular matrix organization and disassem-
bly, cell and cell-matrix adhesion), local inflammation
(immune and inflammatory responses, chemotaxis), and
cell proliferation (mitotic cell cycle, positive regulation
of proliferation) associated with the “poor-prognosis
genes”. Pathways associated with the “good-prognosis
genes” included those related to pancreas metabolism
(endocrine pancreas development, energy reserve meta-
bolic process, insulin secretion) or synaptic connections
(synaptic transmission and vesicle exocytosis, membrane
depolarization during action potential). Whether the 25
a b c d
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Fig. 2 Overall survival (OS) in the validation set according to our prognostic 25-gene classifier and the molecular subtypes. Kaplan–Meier OS curves
according to our prognostic classifier (STS-like and LTS-like classes) and the molecular subtypes defined by Bailey (a pancreatic progenitor; b immunogenic;
c ADEX; d squamous), Collison (e exocrine-like; f classical; g quasi-mesenchymal), and Moffitt (h classical; i basal-like). The P values (log-rank test) for the
comparison between the two classes within each molecular subtype are indicated
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classifier genes are causative of the phenotype in a bio-
logical sense or reflect another associated phenomenon
remain to be explored. However, it was interesting to
find some genes already reported as associated with
cancer biology and/or to the clinical outcome of cancer
patients. Among the genes upregulated in STS, GPR87,
RAC2, NAMPT, C16orf74, TREM2, and CD180 are in-
volved in NF-KB-mediated cell signaling, and KRT13,
RAC2, C16orf74, ADGRG6, and APBB1IP in epithelial–
mesenchymal transition. These two pathways are fre-
quently affected in pancreatic ductal adenocarcinoma
(PDAC) [42, 43]. Activation of the NF-KB signaling path-
way plays an important role in the development and
progression of disease and impacts the epithelial–mesen-
chymal transition, chemoresistance, migration, and inva-
sion of pancreatic cancer cells [42, 44–46]. The NF-KB
activation pathway picked by our signature might not
necessarily be related to tumor cells themselves. Stromal
cells can modulate their activation status through NF-
KB, based on the signals collected from their environ-
ment. TREM2 and CD180 are negative regulators of the
Toll-like receptor pathway [47], a family of receptors
that recognize damage-associated molecule patterns,
whose increased serum levels have been associated with
cancer [48]. Inhibition of Toll-like receptors results in
impaired immediate host defensive responses and anti-
tumor response mounting. TREM2 and CD180 are also
part of the conventional markers used to describe “alter-
natively” activated M2 macrophages. M2 macrophages
promote angiogenesis, tissue remodeling and repair, thus
facilitating tumor progression and invasion, and their
presence is correlated with poor prognosis in several
cancers, including PDAC [49, 50]. Identifying molecules
that modulate some specific “activation nodes” of the
wide NF-KB signaling pathway could be interesting for
pancreatic cancer therapy. Two other genes related to
NF-KB activation are GPR87 and NAMPT, and represent
potential therapeutic targets. GPR87 is overexpressed in
various cancers, including pancreatic cancer cells and
tissues, and its overexpression correlates with shorter
OS [51]. GPR87 enhances pancreatic cancer aggressive-
ness by activating the NF-KB signaling pathway, and
plays a role in tumor cell survival [52, 53] and the regu-
lation of TP53 [54]. Antagonists of GPR87 are in devel-
opment [53]. NAMPT is one of the two enzymes
regulating the NAD+ salvage pathway, a vital pathway
allowing pancreatic cancer cells to maintain their metab-
olism, notably in hypoxic conditions [55]. NAMPT is
also involved in tumor angiogenesis [56, 57]. Thus, tar-
geting NAMPT may not only disturb the salvage path-
way on which pancreatic tumor cells heavily rely, but
may also “normalize” blood vessels in the tumor, a
phenomenon that will improve the delivery and efficacy
of anticancer treatments and relieve immunosuppression
[58, 59]. Several NAMPT inhibitors are currently in
development in oncology [60]. For example, FK866, a
non-competitive highly specific inhibitor of NAMPT,
shows potent anti-tumor activity both in vitro and in
vivo [61] on pancreatic cancer samples overexpressing
NAMPT mRNA. Among the other genes of our signa-
ture upregulated in STS samples are C16orf74 and
KRT13, which are associated with poor OS in pancreatic
[62] and prostate [63] cancers.
Thirteen genes of our signature were downregulated
in STS samples. Three of them, EGR3, EPHA7, and
MACROD2, play a role in peripheral nervous system
biology, which may have a role in PDAC aggressiveness
[64]. We previously reported that the MACROD2 locus
at chromosome 20p12.1 may be a cancer-specific fragile
site often affected in PDAC [65]. Four genes (EPHA7,
SOCS2, SYNM, WNK2) are tumor suppressor genes
whose hypermethylation is a common mechanism of
downregulation. WNK2 is a serine-threonine kinase in-
volved in the regulation of electrolyte homeostasis, cell
survival, and proliferation. Its downregulation occurs early
in PDAC oncogenesis [66]. SOCS2 is an important regula-
tor of the JAK-STAT pathway [67]. SYNM is a type IV
intermediate filament involved in the modulation of cell
adhesion and motility; in breast cancer, SYNM methylation
is associated with shorter recurrence-free survival [68].
Conclusions
We have identified a 25-gene classifier associated with
post-operative OS independently of classical prognostic
factors and molecular subtypes. The strength of our
study lies in the size of the series, the robustness of the
classifier in a large and multicentric validation set and in
each dataset separately, its independent prognostic value,
its non-random nature, and the biological relevance of the
included genes. The small number of genes should
facilitate the clinical application of the classifier by using
other transcriptional tests applicable to formaldehyde-
fixed paraffin-embedded samples such as qRT-PCR, RNA-
scope™ or Nanostring™ technologies. Limitations include
the retrospective nature of our series and associated
biases. Despite the very high P values, the HR for death
was relatively low, around 2, in both uni- and multivariate
analyses, and therefore of uncertain clinical value. How-
ever, we think that the testing of our signature in the
current prospective trials of adjuvant and neoadjuvant
chemotherapy trials is warranted, and should be tested
not only as a two-tiered classifier, but also as a continu-
ous score. Indeed, a continuous score based on the ex-
pression of 25 genes showed significant prognostic
value (data not shown) in univariate analysis (HR for
death of 2.84 (95% CI 2.06–3.91), P = 1.96 × 10–10) and
in multivariate analysis (HR for death of 3.25 (95% CI
2.11–4.99), P = 7.42 × 10–8). If validated, our signature
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could help select patients with resectable disease for
either immediate surgery (for the predicted LTS-like
patients) or neoadjuvant chemotherapy (for the pre-
dicted STS-like patients), which ultimately should affect
outcome and impact quality of life. Of course, the clin-
ical utility of this approach will have to be prospectively
demonstrated prior to any use in clinical routine. Neo-
adjuvant chemotherapy, currently mainly based on ana-
tomical considerations, might also be indicated, and its
benefits maximized, on the basis of the expression profile
of aggressiveness, regardless of resectability. Finally, some
of the classifier genes, or the pathways in which they are
involved, may represent therapeutic targets. Therefore,
functional studies to assess this are warranted.
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